• Michael Pfaller, Dionissios Neofytos, Daniel Diekema, Nkechi Azie, Herwig-Ulf Meier-Kriesche, Shun-Ping Quan, and David Horn.
• JMI Laboratories, North Liberty, IA 52317, USA. michael-pfaller@jmilabs.com
• Diagn. Microbiol. Infect. Dis. 2012 Dec 1;74(4):323-31.

AbstractThis analysis describes the epidemiology and outcomes of candidemia in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance®) registry from 2004 to 2008. Overall, 4067 Candida isolates were identified from 3648 patients. The most common Candida spp. were C. albicans (42.1%), C. glabrata (26.7%), C. parapsilosis (15.9%), C. tropicalis (8.7%), and C. krusei (3.4%). The proportion of candidemia caused by non-albicans Candida spp. (57.9%) was higher than that caused by C. albicans (42.1%). Infections with C. albicans were most common in neonatal intensive care unit (54.8%). In total, 3342 patients received antifungal therapy; fluconazole (66.0%) and echinocandins (50.5%) were most frequently administered. The 90-day survival rate for all patients was 61.3%. Among the most common Candida spp., the highest 90-day survival rate was observed for C. parapsilosis (70.0%) and the lowest for C. krusei (53.6%). In conclusion, this study expands the current knowledge of the epidemiology and outcomes of candidemia.Copyright © 2012 Elsevier Inc. All rights reserved.

14 keywords...

hide…